We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TransMedics (TMDX) Acquires Summit Aviation for Organ Transplant
Read MoreHide Full Article
TransMedics Group, Inc. (TMDX - Free Report) , in a strategic move to revolutionize organ transplant therapy, has successfully concluded the acquisition of Summit Aviation, a premier U.S. charter flight operator. The acquisition marks a pivotal step forward for TransMedics, positioning it as a leading player in the realm of organ transplantation logistics.
The financial terms of the deal, however, remained undisclosed.
Introducing TransMedics Aviation
TransMedics' acquisition of Summit Aviation sets the stage for the establishment of TransMedics Aviation, a pioneering endeavor that will serve as the first integrated national provider of air logistics dedicated exclusively to organ transplantation within the United States. This latest step signifies TransMedics' dedication to enhancing the reach and coverage of the National OCS Program.
Strategic Alignment
The acquisition is hailed as a cornerstone of TransMedics' overarching strategy, seamlessly aligning Summit Aviation's advanced air charter services and strong team culture with TransMedics' globally recognized clinical expertise and cutting-edge transplant technology. This alignment positions TransMedics to not only maintain but elevate its reputation for providing world-class clinical services and state-of-the-art transplant solutions.
Ben Walton, founder and president of Summit Aviation, expressed excitement about the partnership, highlighting the collective ability to revolutionize transplant aviation. The union of TransMedics' groundbreaking Organ Care System and Summit Aviation's aviation prowess promises to reshape organ transportation, ultimately saving more lives.
Image Source: Zacks Investment Research
Market Prospects
The global organ transport devices market holds promise. A Future Market Insights report revealed its value at approximately $105.9 million in 2021 stated that it has a projected CAGR of 8.7% from 2022 to 2032.
Technological advancements have elevated healthcare services and quality, particularly in organ transplantation. As demand for organ transplants rises, increased investments and research in new organ care products are expected to drive the market's growth, indicating a brighter future for improved organ transportation methods.
Share Price Performance
In the past year, TMDX shares have risen 45.8% against the industry’s decline of 3.8%.
Zacks Rank and Key Picks
TransMedics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Penumbra, Inc. (PEN - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Patterson Companies, Inc. .
Penumbra, carrying a Zacks Rank of 1 (Strong Buy), reported second-quarter 2023 adjusted earnings per share (EPS) of 43 cents, beating the Zacks Consensus Estimate by 53.6%. Revenues of $261.5 million outpaced the consensus mark by 3.3%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra has an estimated growth rate of 57.9% for 2024. PEN’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 94.2%.
Patterson Companies sports a Zacks Rank of 1. PDCO has an estimated long-term growth rate of 9.2%.
Patterson Companies’ earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 4.5%.
Integer Holdings reported second-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 15.2%. Revenues of $400 million surpassed the Zacks Consensus Estimate by 8.9%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 12.1%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
TransMedics (TMDX) Acquires Summit Aviation for Organ Transplant
TransMedics Group, Inc. (TMDX - Free Report) , in a strategic move to revolutionize organ transplant therapy, has successfully concluded the acquisition of Summit Aviation, a premier U.S. charter flight operator. The acquisition marks a pivotal step forward for TransMedics, positioning it as a leading player in the realm of organ transplantation logistics.
The financial terms of the deal, however, remained undisclosed.
Introducing TransMedics Aviation
TransMedics' acquisition of Summit Aviation sets the stage for the establishment of TransMedics Aviation, a pioneering endeavor that will serve as the first integrated national provider of air logistics dedicated exclusively to organ transplantation within the United States. This latest step signifies TransMedics' dedication to enhancing the reach and coverage of the National OCS Program.
Strategic Alignment
The acquisition is hailed as a cornerstone of TransMedics' overarching strategy, seamlessly aligning Summit Aviation's advanced air charter services and strong team culture with TransMedics' globally recognized clinical expertise and cutting-edge transplant technology. This alignment positions TransMedics to not only maintain but elevate its reputation for providing world-class clinical services and state-of-the-art transplant solutions.
Ben Walton, founder and president of Summit Aviation, expressed excitement about the partnership, highlighting the collective ability to revolutionize transplant aviation. The union of TransMedics' groundbreaking Organ Care System and Summit Aviation's aviation prowess promises to reshape organ transportation, ultimately saving more lives.
Image Source: Zacks Investment Research
Market Prospects
The global organ transport devices market holds promise. A Future Market Insights report revealed its value at approximately $105.9 million in 2021 stated that it has a projected CAGR of 8.7% from 2022 to 2032.
Technological advancements have elevated healthcare services and quality, particularly in organ transplantation. As demand for organ transplants rises, increased investments and research in new organ care products are expected to drive the market's growth, indicating a brighter future for improved organ transportation methods.
Share Price Performance
In the past year, TMDX shares have risen 45.8% against the industry’s decline of 3.8%.
Zacks Rank and Key Picks
TransMedics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Penumbra, Inc. (PEN - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Patterson Companies, Inc. .
Penumbra, carrying a Zacks Rank of 1 (Strong Buy), reported second-quarter 2023 adjusted earnings per share (EPS) of 43 cents, beating the Zacks Consensus Estimate by 53.6%. Revenues of $261.5 million outpaced the consensus mark by 3.3%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra has an estimated growth rate of 57.9% for 2024. PEN’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 94.2%.
Patterson Companies sports a Zacks Rank of 1. PDCO has an estimated long-term growth rate of 9.2%.
Patterson Companies’ earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 4.5%.
Integer Holdings reported second-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 15.2%. Revenues of $400 million surpassed the Zacks Consensus Estimate by 8.9%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 12.1%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.